Lista de obras -

Acute hepatic failure in the course of alcohol-paracetamol syndrome--case report.

artículo científico publicado en 2003

Agranulocytosis during treatment of chronic hepatitis C complicated by hyperthyreosis. Case reports

artículo científico publicado el 1 de enero de 2012

Anthrax as a pathogen for a biological weapon

artículo científico publicado en 2003

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4.

artículo científico publicado en 2013

Budd-Chiari syndrome--from diagnosis to treatment--case reports

artículo científico publicado en 2008

Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?

artículo científico publicado en 2014

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

artículo científico publicado en 2020

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

artículo científico publicado en 2019

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

artículo científico publicado en 2021

Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively

artículo científico publicado en 2012

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

artículo científico publicado en 2021

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

artículo científico publicado en 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

artículo científico publicado en 2022

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

artículo científico publicado en 2018

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

artículo científico publicado en 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

artículo científico publicado en 2020

Monoexponential and Biexponential Fitting of Diffusional Magnetic Resonance Imaging Signal Analysis for Prediction of Liver Fibrosis Severity

artículo científico publicado en 2019

Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha

artículo científico publicado en 2008

Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors

artículo científico

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

artículo científico publicado en 2019

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

artículo científico publicado en 2019

Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors

artículo científico publicado en 2015

The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.

artículo científico publicado en 2015

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

scholarly article by Ewa Janczewska et al published 16 November 2018 in BMC Infectious Diseases

Treatment with natural interferon (alfaferone) in clinical practice--our experience

artículo científico publicado en 2007

[Borreliosis--increasing clinical problem]

artículo científico publicado en 2006

[Forecasting of efficacy of chronic hepatitis B therapy]

artículo científico publicado en 2012

[Prevalence of borreliosis among forestry workers in Kujawsko-Pomorskie voivodeship]

scientific article published on 01 January 2007

[Treatment of chronic hepatitis B]

scientific article published on 01 January 2004

Lista de obras de

Acute hepatic failure in the course of alcohol-paracetamol syndrome--case report.

Agranulocytosis during treatment of chronic hepatitis C complicated by hyperthyreosis. Case reports

Anthrax as a pathogen for a biological weapon

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4.

Budd-Chiari syndrome--from diagnosis to treatment--case reports

Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

Monoexponential and Biexponential Fitting of Diffusional Magnetic Resonance Imaging Signal Analysis for Prediction of Liver Fibrosis Severity

Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha

Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors

The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

Treatment with natural interferon (alfaferone) in clinical practice--our experience

[Borreliosis--increasing clinical problem]

[Forecasting of efficacy of chronic hepatitis B therapy]

[Prevalence of borreliosis among forestry workers in Kujawsko-Pomorskie voivodeship]

[Treatment of chronic hepatitis B]